Description
Lentivirus express NY-ESO-1-specific T Cell Receptor (TCR) (Clone 1G4), containing no any antibiotic selection
The TCR construct express the antibody specifically recognizes the antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1). The TCR α chain variable region with a transmembrane (TM) domain and β chain variable region with a transmembrane (TM) domain, are linked by F2A element, as “TCRα(V)/Tm-F2A-TCRβ(V)/Tm”
The “target-specific TCRαV and TCRβV sequences” are derived from the verified clones according to published literatures. It does not contain any antibiotic selection marker, trying to minimize the marker’s possible immunogenicity. see the Lentivector scheme below
About NY-ESO-1 (tumor epitope NY-ESO-1):
NY-ESO-1, short for New York Esophageal Squamous Cell Carcinoma 1, is a cancer-testis antigen, which means it is a protein normally expressed in embryonic testes but not in normal adult tissues. It has been found to be expressed in various cancer types, including melanoma, breast cancer, and ovarian cancer. The unique expression pattern of NY-ESO-1 makes it an attractive target for cancer immunotherapy.
This TCR Lentivirus specifically recognize the tumor epitope SLLMWITQC at NY-ESO-1 (157-165), aims to provide a targeted and effective treatment for certain types of cancers.
References: Ref 1.
see details in Product Manual.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1683
